Xvivo Perfusion AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XVIPY research report →
About the company
Xvivo Perfusion AB (publ), a medical technology enterprise based in Gothenburg, Sweden, specializes in developing cutting-edge solutions for the preservation and perfusion of organs, tissues, and cells, crucial for transplantation. The company's reach spans diverse global markets, including Sweden, the United States, broader North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its extensive product lineup features the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP).
- CEO
- Christoffer Rosenblad
- IPO
- 2022
- Employees
- 170
- HQ
- Gothenburg, SE
Price Chart
- Market Cap
- $898.21M
- P/E
- 119.66
- P/S
- 10.57
- P/B
- 4.07
- EV/EBITDA
- 56.09
- Div Yield
- 0.00%
- Gross Margin
- 65.21%
- Op Margin
- 11.79%
- Net Margin
- 8.85%
- ROE
- 3.49%
- ROIC
- 3.28%
- Revenue
- $763.43M · -7.17%
- Net Income
- $23.65M · -86.26%
- EPS
- $0.19 · -86.29%
- Op Income
- $87.44M
- FCF YoY
- -82.98%
- 52W High
- $7.25
- 52W Low
- $4.25
- 50D MA
- $5.27
- 200D MA
- $5.27
- Beta
- 1.77
- Avg Volume
- 2.05K
Get TickerSpark's AI analysis on XVIPY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our XVIPY coverage
Recent articles, reports, and earnings notes.
No research on XVIPY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XVIPY report →Similar companies
Peers in the same neighborhood.